Phase II trial of 4'-epi-doxorubicin in advanced carcinoma of head and neck origin.

Thirty-one patients with advanced head and neck cancer were treated with 4'-epidoxorubicin. Three of 25 evaluable patients with squamous cell carcinoma and two of three with minor salivary gland carcinoma had partial remissions. Four patients received cumulative doses of 680-1270 mg/m2; none developed clinical heart failure.